Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents? | Berek et al. Child and Adolescent Psychiatry and Mental Health 2011 5 26 http www.capmh.eom content 5 1 26 CHILD ADOLESCENT PSYCHIATRY MENTAL HEALTH RESEARCH Open Access Improved functionality health related quality of life and decreased burden of disease in patients with ADHD treated with OROS MPH is treatment response different between children and adolescents K I i r- A r- I o X r dz 1 A rd V C I I IX r rrd r 2 I I I rd f r I_I zri n rb w3 Eril-- s4-4-z i X f 4 I í r í Cl tA ỉ I 3 ì I I I r D 1 z t 5 nn rd Michael BereK Andreas Kordon Ludger nargarter Fritz Mattejat Lara SlawiK Klaus Kenig ana Barbara Schauble3 Abstract Background To compare clinical and health-related quality of life HRQoL outcomes between children and adolescents with ADHD treated with OROS MPH using data from two large similarly-designed multicenter prospective open-label single-arm non-interventional studies. Methods Pooled analysis 42603ATT4037 42603 - ATT - 4001 including patients 6 to 18 years with a confirmed diagnosis of ADHD. Patients were treated with OROS MPH for 12 weeks ADHD symptoms functioning HRQoL safety and tolerability parameters were assessed. Results 822 patients 583 children 6-12 years 239 adolescents 13-18 years were included in the pooled analysis. Mean daily OROS MPH starting doses in the child and adolescent subgroups were 29.0 11.7 and 37.6 15.6 mg respectively p 0.001 . At study end week 12 the overall mean daily dose was 35.5 14.0 mg with children and adolescents receiving 32.8 12.7 and 42.0 15.1 mg day respectively p 0.001 . Significant p 0.0001 overall population children adolescents symptomatic functional and HRQoL improvements were observed from baseline to study end using the Conners Parents Rating Scale overall 29.2 10.7 baseline to 19.3 11.3 endpoint Children s Global Assessment Scale overall 58.5 14.5 baseline to 69.6 16.1 endpoint and ILC-LQ0-28. At week 12 between-age group differences were seen in the individual ILC-LQ0-28 parameters school performance p